Natriuretic peptides have been of research interest for more than 2 decades [1, 2] but gained real clinical importance within just the past few years. Atrial natriuretic factor was extracted in 1981 [3] . In 1988, a second natriuretic peptide was identified in porcine brain. Initially, it was called brain natriuretic peptide, but after the ventricular myocardium was noted as the main source, it is now typically referred to as B-type natriuretic peptide (BNP). Right and left ventricular myocardium excretes BNP in response to fluid overload and wall stress in congestive heart failure [4] . BNP is cleared via hydrolysis by neutral endopeptidase, via cell binding followed by enzymatic degradation and via filtration in the kidney. Interaction with natriuretic peptide receptor A, located on the cells of target organs, results in vasodilation (including coronary vasodilation), natriuresis, and diuresis. BNP also appears to decrease aldosterone, norepinephrine, and endothelin 1 levels. It has inhibiting properties on the renin-angiotensin-aldosterone system [5, 6] .
The diagnostic value of endogenous BNP levels in the differential diagnosis and management of heart failure has been the focus of multiple recent studies, and the research in this area will continue for quite some time. A second large area of interest focuses on the therapeutic properties of BNP given as continuous infusion in congestive heart failure.
Nesiritide (Natrecor, Scios Inc, Fremont, Calif) is produced using recombinant DNA techniques and is structurally identical to natural human BNP. It has the same pharmacologic properties and same metabolism. It is available in intravenous form. The average half-life elimination time is about 18 minutes, which leads to a steady-state plasma concentration about 90 minutes after starting a continuous infusion. Adjustment in dosage for patients with renal impairment is usually not necessary [6] .
Recently, nesiritide has gained importance in the treatment of congestive heart failure in adults. The Nesiritide Study Group evaluated 432 patients who required hospitalization and intravenous therapy for decompensated heart failure. Inotropic medications were discontinued, and patients were assigned to different groups, including placebo, nesiritide at 0.015, nesiritide at 0.03 mcg/kg/min, and standard therapy consisting of a single intravenous vasoactive agent. In comparison to placebo, nesiritide decreased capillary wedge pressure, dyspnea, and fatigue. Clinical status improved in more than 60% of patients. Nesiritide had similar results as standard intravenous therapy for heart failure. The most common side effect was asymptomatic hypotension [7] .
The Vasodilation in the Management of Acute Congestive Heart Failure trial compared 489 patients with congestive heart failure and dyspnea at rest. In a prospective, multicenter, randomized, double-blinded study, patients were assigned to 1 of 3 groups: intravenous nesiritide, intravenous nitroglycerin, or placebo for 3 hours. Thereafter, patients received either intravenous nesiritide or intravenous nitroglycerin for 24 hours. At 3 hours of treatment with nesiritide, there was a significant decrease in pulmonary capillary wedge pressure when compared to nitroglycerin and placebo. This effect was also present at 24 hours. Dyspnea was significantly improved with nesiritide in comparison to placebo at 3 hours, but no difference was present to nitroglycerin at 3 or 24 hours. Significant side effects of nesiritide included headache and hypotension. Hypotension lasted as long as 2 hours [8] .
The Prospective Randomized Evaluation of Cardiac Ectopy With Dobutamine or Natrecor Therapy trial evaluated 255 adult patients with congestive heart failure in New York Heart Association class III and IV. Patients were randomized to lowdose dobutamine or 1 of 2 fixed doses of nesiritide (0.015 and 0.03 mcg/kg/min without bolus) for at least 24 hours. The study design was prospective, multicenter, randomized, and open label. Patients were monitored for development of cardiac arrhythmias with 24-hour Holter monitoring immediately before and during the study period. Dobutamine increased the average number of ventricular tachycardias, premature ventricular beats, and heart rate from baseline. Nesiritide resulted in a greater reduction in blood pressure (17% to 24% of patients developed symptomatic hypotension), but there were significantly less premature ventricular beats, less ventricular tachycardia, and no increase in heart rate from baseline [9] .
Multivariate analysis of more than 33,000 patients enrolled in the Acute Decompensated Heart Failure National Registry showed a significantly lower mortality for patients treated with nesiritide in comparison to milrinone and dobutamine. No significant difference could be demonstrated to nitroglycerin [10] .
Recent pilot studies have been directed at the potential benefits of long-term administration of nesiritide in the form of twice-daily subcutaneous injections or repeated short outpatient infusions. Preliminary data showed good tolerance of the medication with improved diuresis and improved hemodynamic status. Improvement in cardiohumoral function via interruption of the reninangiotensin-aldosterone cascade may result in long-term beneficial effects, especially if compared to intermittent inotropic medications [11, 12] .
Very little data exist in the use of nesiritide in the pediatric population. Sehra and Underwood [13] used nesiritide at doses of 0.005 to 0.02 mcg/kg/min in 7 pediatric patients awaiting heart transplantation. Nesiritide was added to standard therapy. The patients showed improvement in urine output of 22% to 24% from baseline. No significant hypotensive complications were noted.
The adult patient population is very different from the pediatric population with regard to etiology and presentation of cardiac disease. Nesiritide is now commonly used in adults with low-output congestive heart failure. Pediatric congestive heart failure due to congenital heart disease is often the result of high output with preserved myocardial function. The adult data of nesiritide use cannot simply be transferred to these patients. Nevertheless, several properties of nesiritide (eg, diuresis) could be beneficial.
Pediatric patients with cardiomyopathy due to congenital heart disease or myocarditis form a smaller patient population in which nesiritide could be very helpful, assuming that nesiritide produces similar physiologic effects as in the adult population. A potentially larger field of application for nesiritide in pediatrics consists of patients after open heart surgery. Vasodilatation, diuresis, and decreases in aldosterone, norepinephrine, and endothelin 1 levels make nesiritide an attractive alternative to other medications. In addition, its neutral effect on heart rate appears very desirable after complex pediatric intracardiac surgeries where tachycardia (eg, junctional ectopic tachycardia) is rather common. Inotropic medications may actually result in decreased cardiac output due to disproportionate increase in heart rate, which impairs diastolic relaxation and filling.
The studies by Marshall et al [14] and Sehra and Underwood [13] , in addition to unpublished individual experiences in multiple pediatric centers, clearly demonstrate a roll for nesiritide in the pediatric population. Nesiritide appears reasonably safe in pediatric patients at similar maintenance doses as in adults (0.01-0.03 mcg/kg/min). Additional information in larger pediatric studies is needed to learn more about all effects, optimal dosing, and most appropriate applications of nesiritide in pediatrics. Multicenter trials would be an ideal way to evaluate these issues.
